ReviewFrontiers in endocrinology2024
Hypothyroidism and metabolic cardiovascular disease.
Review in Frontiers in endocrinology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- An exploratory study on the changes in immune and metabolic parameters by 10 weeks of yoga intervention among medical students.Scientific reports · 2025Trial
- Review
- Thyroid dysfunction and cardiovascular disease.European heart journal · 2026Review
- The unseen impact of subclinical hypothyroidism on lipid profile and cardiovascular risk.Biochemistry and biophysics reports · 2026Article
- Central hypothyroidism and cardiovascular disease: a Spanish cohort observational study.Hormones (Athens, Greece) · 2026Observational
- The study on serum oxidized low-density lipoprotein and homocysteine as cardiovascular risk markers in subclinical hypothyroidism patients.Frontiers in endocrinology · 2026Article
- Development and external validation of a risk prediction model for hypertension among individuals with established hypothyroidism.Frontiers in endocrinology · 2026Article
- Phenotypic Age Acceleration as a Mediator in Thyroid Hormone-Related Cardiovascular Risk Among the Elderly.Cardiology research and practice · 2026Article
- Impact of Thyroid Hormone Imbalance on Electrocardiographic Parameters: Systematic Review and Meta-Analysis.Journal of clinical medicine · 2025Review
- Cardiomyopathies of endocrine origin: A state-of-the-art review.World journal of cardiology · 2025Review
- Genotype Combinations and Genetic Risk Score Analyses ofCurrent issues in molecular biology · 2025Article
- Association between triglyceride-glucose index and thyroid nodule: a cross-sectional study in Western Liaoning Province, China.Scientific reports · 2025Article
- Is subclinical hypothyroidism associated with cardiovascular disease in the elderly?Endocrine connections · 2025Review
- Association Between Metabolic Syndrome and Subclinical Hypothyroidism: A Systematic Review.Cureus · 2025Review
- Autoimmune Processes and Chronic Inflammation as Independent Risk Factors for Metabolic Complications in Women with Polycystic Ovary Syndrome.Metabolites · 2025Article
- Associations between indicators of lipid and glucose metabolism and hypothyroidism.Lipids in health and disease · 2025Article
- Risk factors and clinical implications of thyroxine replacement therapy on major adverse cardiovascular events in type 2 diabetes: a retrospective cohort study.Frontiers in endocrinology · 2025Article
- Research status of subclinical hypothyroidism promoting the development and progression of cardiovascular diseases.Frontiers in cardiovascular medicine · 2025Review
- Impaired central sensitivity to thyroid hormone is associated with hypertriglyceridemia in euthyroid population.Frontiers in endocrinology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiovascular disease (CVD) remains the leading cause of death worldwide, representing a major health issue of social and economic relevance. Both hyperthyroidism and hypothyroidism are very common in the adult population, and both disorders may contribute to the onset and progression of CVD. After a brief description of the role of thyroid hormones (THs) on the physiology of the cardiovascular system and the potential mechanism that links THs alterations with changes in cardiac function, blood pressure, endothelial function, and lipid levels, we review updated data about the clinical impact of overt hypothyroidism (OH) and subclinical hypothyroidism (SCH) on CV risk, CVD, and mortality. Furthermore, we summarize the current evidence for treating SCH with levothyroxine (L-T4). Several guidelines of distinguished endocrine societies recommend treatment for SCH with TSH higher than 10 mIU/L, where the benefit of L-T4 therapy is more evident for younger people, but still controversial in those aged over 65 years. Based on current knowledge, more research efforts are needed to better address the clinical management of CV risk and CVD in the elderly affected by SCH.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.